OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Elisabetta Sauta, Marie Robin, Matteo Bersanelli, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 15, pp. 2827-2842
Open Access | Times Cited: 63
Elisabetta Sauta, Marie Robin, Matteo Bersanelli, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 15, pp. 2827-2842
Open Access | Times Cited: 63
Showing 1-25 of 63 citing articles:
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
Guillermo Garcia‐Manero
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1307-1325
Open Access | Times Cited: 87
Guillermo Garcia‐Manero
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1307-1325
Open Access | Times Cited: 87
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study
Jurjen Versluis, Wael Saber, Harrison Tsai, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 28, pp. 4497-4510
Open Access | Times Cited: 30
Jurjen Versluis, Wael Saber, Harrison Tsai, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 28, pp. 4497-4510
Open Access | Times Cited: 30
Novel precision medicine approaches and treatment strategies in hematological malignancies
Richard Rosenquist, Elsa Bernard, Tom Erkers, et al.
Journal of Internal Medicine (2023) Vol. 294, Iss. 4, pp. 413-436
Open Access | Times Cited: 16
Richard Rosenquist, Elsa Bernard, Tom Erkers, et al.
Journal of Internal Medicine (2023) Vol. 294, Iss. 4, pp. 413-436
Open Access | Times Cited: 16
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
Cristina Astrid Tentori, Caterina Gregorio, Marie Robin, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 24, pp. 2873-2886
Open Access | Times Cited: 7
Cristina Astrid Tentori, Caterina Gregorio, Marie Robin, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 24, pp. 2873-2886
Open Access | Times Cited: 7
Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms
Pasquale Niscola, Valentina Gianfelici, Marco Giovannini, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1563-1563
Open Access | Times Cited: 6
Pasquale Niscola, Valentina Gianfelici, Marco Giovannini, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1563-1563
Open Access | Times Cited: 6
Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy
Ignacio Campillo‐Marcos, Marta Casado-Peláez, Verónica Dávalos, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 2, pp. 365-377
Open Access | Times Cited: 5
Ignacio Campillo‐Marcos, Marta Casado-Peláez, Verónica Dávalos, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 2, pp. 365-377
Open Access | Times Cited: 5
Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
Cristina Astrid Tentori, Lin P. Zhao, Benedetta Tinterri, et al.
HemaSphere (2024) Vol. 8, Iss. 5
Open Access | Times Cited: 4
Cristina Astrid Tentori, Lin P. Zhao, Benedetta Tinterri, et al.
HemaSphere (2024) Vol. 8, Iss. 5
Open Access | Times Cited: 4
Challenges in Consensus Regarding the Treatment of Myeloid Malignancies
Hetty E. Carraway
(2025)
Closed Access
Hetty E. Carraway
(2025)
Closed Access
Epidemiology, Treatment Outcomes, and Prognosis of Myelodysplastic Syndromes/Neoplasms in Taiwan: Real-World Insights and Trends
Wan‐Hsuan Lee, Chien‐Chin Lin, Cheng‐Hong Tsai, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Wan‐Hsuan Lee, Chien‐Chin Lin, Cheng‐Hong Tsai, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Real world efficacy of luspatercept in patients with lower-risk myelodysplastic syndromes/neoplasms (MDS); a single center study in a heavily pretreated cohort
Marisa Kometas, Fieke W. Hoff, Jonathan Hyak, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-9
Closed Access
Marisa Kometas, Fieke W. Hoff, Jonathan Hyak, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-9
Closed Access
Immature forms of low density granulocytes are increased in acute myeloid leukemia and myelodysplastic syndromes
A. Bertolini, Francesca Picone, Idalucia Ferrara, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
A. Bertolini, Francesca Picone, Idalucia Ferrara, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Perspectives on Current Challenges and Emerging Approaches for the Management of CH, MDS, and AML From the 1st Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference
Hetty E. Carraway, Andrew M. Brunner, Catherine Lai, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Hetty E. Carraway, Andrew M. Brunner, Catherine Lai, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
The Progress in Diagnosis and Treatment of Myelodysplastic Syndromes
理超 杜
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 1707-1715
Closed Access
理超 杜
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 1707-1715
Closed Access
The impact of mutational burden, spliceosome and epigenetic regulator mutations on transfusion dependency in dysplastic neoplasms
Bernhard Strasser, Sebastian Mustafa, Rita Steindl, et al.
Journal of Laboratory Medicine (2025)
Open Access
Bernhard Strasser, Sebastian Mustafa, Rita Steindl, et al.
Journal of Laboratory Medicine (2025)
Open Access
Efficacy and safety of decitabine combined with arsenic trioxide in elderly high-risk myelodysplastic neoplasm patients: a retrospective study
Jianzhong Yang
Hematology (2025) Vol. 30, Iss. 1
Open Access
Jianzhong Yang
Hematology (2025) Vol. 30, Iss. 1
Open Access
Using Artificial Intelligence to Enhance Myelodysplastic Syndrome Diagnosis, Prognosis, and Treatment
Fabio Stagno, Giuseppe Mirabile, Patricia Rizzotti, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 835-835
Open Access
Fabio Stagno, Giuseppe Mirabile, Patricia Rizzotti, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 835-835
Open Access
Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification
Wan‐Hsuan Lee, Ming-Tao Tsai, Cheng‐Hong Tsai, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Wan‐Hsuan Lee, Ming-Tao Tsai, Cheng‐Hong Tsai, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Clinical decision-making and treatment of myelodysplastic syndromes
Eva S. Hellström-Lindberg, Nicolaus Kröger
Blood (2023) Vol. 142, Iss. 26, pp. 2268-2281
Closed Access | Times Cited: 11
Eva S. Hellström-Lindberg, Nicolaus Kröger
Blood (2023) Vol. 142, Iss. 26, pp. 2268-2281
Closed Access | Times Cited: 11
The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes
Amy E. DeZern, Peter L. Greenberg
Blood (2023) Vol. 142, Iss. 26, pp. 2258-2267
Closed Access | Times Cited: 7
Amy E. DeZern, Peter L. Greenberg
Blood (2023) Vol. 142, Iss. 26, pp. 2258-2267
Closed Access | Times Cited: 7
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens
Marie Sébert, Lucie Freiman, Cendrine Chaffaut, et al.
Leukemia (2024) Vol. 38, Iss. 4, pp. 918-922
Closed Access | Times Cited: 2
Marie Sébert, Lucie Freiman, Cendrine Chaffaut, et al.
Leukemia (2024) Vol. 38, Iss. 4, pp. 918-922
Closed Access | Times Cited: 2
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee
Francesco Onida, Nico Gagelmann, Yves Chalandon, et al.
Blood (2024) Vol. 143, Iss. 22, pp. 2227-2244
Open Access | Times Cited: 2
Francesco Onida, Nico Gagelmann, Yves Chalandon, et al.
Blood (2024) Vol. 143, Iss. 22, pp. 2227-2244
Open Access | Times Cited: 2
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
Rami S. Komrokji, Luca Lanino, Somedeb Ball, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 11, pp. e862-e872
Closed Access | Times Cited: 2
Rami S. Komrokji, Luca Lanino, Somedeb Ball, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 11, pp. e862-e872
Closed Access | Times Cited: 2
Impact of IPSS-M implementation in real-life clinical practice
Irene Zamanillo, María Poza, Rosa Ayala, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Irene Zamanillo, María Poza, Rosa Ayala, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Evaluation of new IPSS-Molecular model and comparison of different prognostic systems in patients with myelodysplastic syndrome
Jiale Ma, Yan Gu, Yanhui Wei, et al.
Blood Science (2023)
Open Access | Times Cited: 5
Jiale Ma, Yan Gu, Yanhui Wei, et al.
Blood Science (2023)
Open Access | Times Cited: 5
A novel t(X;21)(p11.4;q22.12) translocation adds to the role of BCOR and RUNX1 in myelodysplastic syndromes and acute myeloid leukemias
Elena Mavridou, Anair Graciela Lema Fernandez, Carlotta Nardelli, et al.
Genes Chromosomes and Cancer (2024) Vol. 63, Iss. 4
Open Access | Times Cited: 1
Elena Mavridou, Anair Graciela Lema Fernandez, Carlotta Nardelli, et al.
Genes Chromosomes and Cancer (2024) Vol. 63, Iss. 4
Open Access | Times Cited: 1
